Intas Pharma Share, Keep in mind, this pipeline analysis is ba
Intas Pharma Share, Keep in mind, this pipeline analysis is based mostly on potential players who have undertaken Phase 3 trials of their investigational products. 00%) 03 Dec 09 | 09:33 | All Prices in See Intas Pharmaceuticals funding rounds, investors, investments, exits and more. This price reflects the company’s growth opportunities, supported and backed by expansion plans and strategies focused on both production manufacturing and research centers. 20 Nov, 2025, 11:26 AM IST Sudeep Pharma IPO: GMP jumps The face value of Intas Pharmaceuticals share is ₹10 per share along with the Intas share price in the unlisted market at approximately ₹5,800 per share. At this GMP, the stock is expected to list near ₹723, signalling a potential upside of about ₹130 per share. Liked by Anoop Singh Chandel 🔬 Pharmaceutical Microbiology Quick Fact Environmental Monitoring trending is not about preparing monthly or quarterly reports. Reddy’s laboratories, Torrent Pharmaceuticals and Cipla Ltd. 21,200Cr for the financial year ending on Mar 31, 2025. Company's authorized capital stands at Rs 1500. This guide unpacks its products, revenues, corporate structure, stocks/share notes, local hiring and strategic moves. Short intro: Intas Pharmaceuticals is an Ahmedabad-headquartered multinational pharma group focused on generics, biosimilars and global supply via Accord Healthcare. Watch videos, top stories and articles on Intas Pharmaceuticals at moneycontrol. In this article, we will delve into an analysis of Intas Overview Gujarat has become a hub for the pharmaceutical industry, with several established companies such as Torrent Pharmaceuticals, Zydus Lifesciences, Cadila Pharmaceuticals, Alembic Pharmaceuticals, Sun Pharma, Claris, Intas Pharmaceuticals, and Dishman Pharmaceuticals having operations in the state. Intas Pharmaceutical Ltd has been rated by 4. are the major companies operating in this market. 4 lakhs. Accord Healthcare, based in the United Kingdom, markets generic and biosimilar medicines across Europe and other global markets. "Stepping into a new chapter with curiosity and drive 📚" | 102 comments on LinkedIn Intas Pharmaceuticals, headquartered in Ahmedabad, operates in more than 85 countries and maintains capabilities across formulation development, manufacturing, biosimilars and active pharmaceutical ingredients. INTAS PHARMACEUTICALS Ltd (INTAS6NOV09 | 946397 | INE316F07018) 0. Its robust product portfolio consists of 13 commercialized products and a promising pipeline of 6 products. Uncover all the details of Instas Pharmaceuticals's successful journey. It's been a while since I started my role at Emcure Pharmaceuticals Limited as a Manager, but I wanted to share this update with everyone. Get detailed report, 52 Week High / Low and company news on Nirmal Bang INTAS PHARMACEUTICALS Ltd (INTAS6NOV09 | 946397 | INE316F07018) 0. A few players new to the US biosimilar market also appear, such as Gedeon Richter and Intas. 97638% paid-up capital which is Rs 11474. Get detailed report, 52 Week High / Low and company news on Nirmal Bang The ratings reaffirmation of Intas Pharmaceuticals Limited (IPL) factors in its well diversified geographical presence and a strong position across its key markets. Intas Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad. 41% (3. It's a public unlisted company and is classified as'company limited by shares'. SUMMARY BOX — QUICK VALUE (What you'll learn / Key statistics) quote options Equity T+1 Equity T+0 Derivatives MF/ETFs Debt/Others Currency Derivatives Commodity Derivatives Electronic Gold Receipts Hybrid Security Municipal Dominant position in domestic formulation market supported by larger share in the chronic therapeutic segment IPL is the seventh (sixth as on December 31, 2023) largest pharmaceutical player in the domestic formulation market with a market share of 3. Intas is one of the leading multinational pharmaceutical formulation development, manufacturing and marketing companies in the world. Currently, I am a B. 9% market share. is a leading vertically integrated pharmaceutical company based in Ahmedabad, India, having end-to-end capabilities of formulation development, manufacturing and Intas Pharma is an unlisted pharma companies in India, a prominent global player in formulation development, manufacturing, and marketing, and stands as a significant healthcare contender among the top 10 unlisted companies in India. is a Non-govt company, incorporated on 21 Mar, 2000. Driven by a sustainable business model, Intas has been consistently outperforming the market with a 14% CAGR. It’s about real time… Liked by Anoop Singh Intas Pharmaceuticals Limited produces pharmaceutical products. I am happy to share that I’ve joined Intas Pharmaceuticals as an Assistant General Manager - Projects. Given the positive indicators in terms of revenue growth and profitability, the company appears to be fairly valued, presenting a promising investment opportunity for investors. 10 each (Equity Shares) of Intas Pharmaceuticals Limited (The company or The Issuer) for cash at a price of Rs. Biologics Business Unit Intas’ Biologics Business Unit was launched in 2000 with a focus on developing high-quality recombinant DNA protein (rDNA) products and plasma-derived products. Aurobindo Pharma may buy Portugal's Generis, deal likely to be valued at $200 million Aurobindo's latest bid comes on the heels of last month’s shot at Israeli drug maker Teva's UK product portfolio, where it was outbid by rival Intas Pharmaceuticals. Factoring in the discounts, the share price falls within the range of ₹4,753 to ₹5,092. Company's authorized capital stands at Rs 17391. Intas Pharmaceuticals Limited is one such private pharmaceutical manufacturing company that is engaged in the formulation, manufacturing, and marketing of pharmaceuticals with its headquarters in Ahmedabad, Gujarat. Investing in the stock market involves understanding various companies, their performance, and potential growth prospects. Intas Pharma (Amalgam Stock Price - Get Intas Pharma (Amalgam Live BSE/NSE stock price with historical charts (NSE/BSE), forecasts, financial reports, balance sheet, profit & loss, annual report, analyst ratings, and more Aurobindo Pharma may buy Portugal's Generis, deal likely to be valued at $200 million Aurobindo's latest bid comes on the heels of last month’s shot at Israeli drug maker Teva's UK product portfolio, where it was outbid by rival Intas Pharmaceuticals. [10] In terms of the global market, India currently holds an accountable share and is known as the pharmacy of the world. Get detailed report, 52 Week High / Low and company news on Nirmal Bang. com. Get all latest & breaking news on Intas Pharmaceuticals. 0 lakhs and has 100. 6%2. [*] crores (The Issue Overview Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company. [*] per equity share including a share premium of Rs. Intas Pharma Limited. Today, Intas is present in more than 85 countries worldwide and is growing at ~22% CAGR. Analyze Intas Biopharmaceuticals Ltd - (Amalgamated)’s fundamentals including revenue, profit, EPS, ratios, and more. 00%) 03 Dec 09 | 09:33 | All Prices in Public issue of upto [*] equity shares of face value of Rs. com Intas Pharma Job vacancy for Mechanical Engineer apply now Intas-pharma-share-price News: Get the latest Intas-pharma-share-price news, photos, videos, and podcasts. [14] Intas Pharma Limited. Due to a sustainable growth strategy and robust business model, Intas has achieved a healthy top and bottom line, year on year. [*] per equity share, aggregating up to Rs. Updated Feb 2026: Is Intas Pharma Ltd. Analyze Intas Pharma Ltd. Intas Pharma Job vacancy for Mechanical Engineer apply now How to apply Interested Candidates send CV Below Mail Id recruitment_hr@intaspharma. 74 billion by 2031. [3] I am delighted to share that I have joined Intas Pharmaceuticals as a Management Trainee – Regulatory Affairs. Are you looking for Intas Pharmaceuticals Limited financials? Visit Tofler for its net worth, ratios, profit and loss, competition, products, industry, and financial analysis. INTAS PHARMACEUTICALS LIMITED generated a revenue of Rs. 0% paid-up capital which is Rs 1500. It is also among the leading Indian generic formulation manufacturers in Europe with a strong p esence in the UK. last annual From detailed reviews to simple star ratings, every comment helps you better understand what to expect from a particular company's services. 74% to reach USD 79. [*] crores (The Issue t share of 3. 0. Sun Pharmaceutical Industries Limited, Cipla Pharmaceuticals, Dr. Intas is committed to challenging the unmet medical and societal needs through a comprehensive pharmaceutical value chain spanning across the world. Stay updated with the latest earnings calls, annual reports, and company filings. Find comprehensive investor information about Intas Pharmaceuticals Ltd. Get in-depth insights into Intas Pharma Ltd. The company’s successful track record of landmark acquisitions is built entirely on the foundation of robust financial strength. Explore more for Intas-pharma-share-price breaking news, opinions, special reports, and . 1,147,695,490. Dominant position in domestic formulation market supported by larger share in the chronic therapeutic segment IPL is the seventh (sixth as on December 31, 2023) largest pharmaceutical player in the domestic formulation market with a market share of 3. INDIA Currently ranked at 7 th (As per IQVIA TSA June 2022 MAT) in the Indian Pharmaceutical Market, Intas is one of the fastest growing Indian pharmaceutical majors, having 3. IPL is one of the first Indian companies to launch biosimilar products in the European markets and has three pr Intas Pharma is likely to file Draft Red Herring Prospectus (DRHP) with Securities and Exchange Board of India (Sebi), in the next two weeks. Watch videos, top stories and articles on Intas Pharma at moneycontrol. Note: The share of this listed depository shall only be dealt by fit and proper person as per regulation 22 & 23 of Securities and Exchange Board of India (Depositories And Participants) Regulations, 2018. 67 lakhs and has 65. India's revenue from pharmaceutical exports was $25. [2] It is a producer of generic therapeutic drugs and engaged in contract clinical research and manufacturing. FY 2026 financials, directors, compliance. 1,754,667,520 and its paid up capital is Rs. Intas Pharma (Amalgam Stock Price - Get Intas Pharma (Amalgam Live BSE/NSE stock price with historical charts (NSE/BSE), forecasts, financial reports, balance sheet, profit & loss, annual report, analyst ratings, and more 4 days ago · Check today's Intas Pharma (Amalgam share price live on NSE/BSE with chart, performance, fundamentals, P&L, balance sheet, financial reports & profile of Intas Pharma Ltd (Amalgamated) (Amalgamated) at Findoc. , including business operations, financials, and growth strategies. Intas Pharmaceuticals Ltd. Pharmacy 3rd year student, actively looking for an internship opportunity where I can gain practical exposure and enhance my technical knowledge in the pharmaceutical field. Updated Feb 2026: Is overvalued or undervalued right now? Get share analysis with business quality, valuation zone and current price trend and DeciZen rating, plus key risks and a long-term investment view. Intas Pharmaceuticals Ltd - Company profile, news, and insights on Fortune India. 03 Nov, 2016, 01:22 AM IST The India Pharmaceuticals Market worth USD 60. These insights can guide you in evaluating whether Intas Pharmaceutical Ltd meets your expectations in Ratu Road, Ranchi. Get detailed report, 52 Week High / Low and company news on Nirmal Bang Currently ranked at 10th in the Indian Pharmaceutical Market, Intas is one of the fastest growing Indian pharmaceutical majors, having 2. Evaluate their financials based on Intas Pharmaceuticals's post-money valuation and revenue. Updated Jan 2026: Is Intas Biopharmaceuticals Ltd - (Amalgamated) overvalued or undervalued right now? Get share analysis with business quality, R&D pipeline and valuation zone and DeciZen rating, plus key risks and a long-term investment view. Est. 1% market share. (Amalgamated) (Amalgamated)'s stock price, historical performance, key financial statements, and peer comparison. The Company develops and manufactures drugs for infertility, gynecology, cardiovascular conditions, diabetes, pain management, and Sudeep Pharma IPO: Shares are seeing solid momentum in the grey market, trading at a 21. 03 Nov, 2016, 01:22 AM IST Updated Jan 2026: Is Intas Biopharmaceuticals Ltd - (Amalgamated) overvalued or undervalued right now? Get share analysis with business quality, R&D pipeline and valuation zone and DeciZen rating, plus key risks and a long-term investment view. Get all latest & breaking news on Intas Pharma. [13] India produces more than 50% the world's vaccines. Detailed valuation available for premium members on MoneyWorks4Me. [LIVE] Intas Pharma (Amalgam share price details along with futures & options quotes. It has decided to revive its IPO plan. Intas Pharmaceuticals, a leading global pharmaceutical company headquartered in India, has garnered significant attention from investors due to its consistent growth trajectory and innovative product pipeline. [12] The country is the largest global supplier of generic medicine. 32 billion in 2026 is growing at a CAGR of 5. (Amalgamated) (Amalgamated) overvalued or undervalued right now? Get share analysis with business quality, R&D pipeline and valuation zone and DeciZen rating, plus key risks and a long-term investment view. Intas Pharmaceuticals Limited is a Non-govt company, incorporated on 31 May, 1985. 0 users, with an average score of 4. 3 billion in the 2022-2023 financial year. 51% as on December 31, 2023) as on March 31, 2023 (Source: company). Check the share price of Intas Pharma (Amalgam today along with its price chart. Market Share of Intas Pharmaceuticals Limited's Largest Competitors A competitive analysis shows these companies are in the same general field as Intas Pharmaceuticals Limited, even though they may not compete head-to-head. Currently ranked at 10th in the Indian Pharmaceutical Market, Intas is one of the fastest growing Indian pharmaceutical majors, having 2. Get in-depth insights into Intas Biopharmaceuticals Ltd - (Amalgamated)'s stock price, historical performance, key financial statements, and peer comparison. INTAS PHARMACEUTICALS LIMITED's authorised share capital is Rs. 0 lakhs. Also, explore detailed financials, key ratios and latest Share holding Pattern of Intas Pharma (Amalgam at CapMint. Driven by a sustainable business model, Intas has been consistently outperforming the market with 15% growth (As per IQVIA TSA June 2022 MAT). 1985. This marks an exciting milestone in my professional journey, and I am truly [LIVE] Intas Pharma (Amalgam share price details along with futures & options quotes. (Amalgamated) (Amalgamated)’s fundamentals including revenue, profit, EPS, ratios, and more. Explore Intas Pharmaceuticals Limited, a pharma public limited company in Ahmedabad, Gujarat, India. 00 (0. Intas Public issue of upto [*] equity shares of face value of Rs. Intas Pharmaceuticals Limited is classified as operating in the Legal Services industry, NAICS Code 5411. 92% premium to the issue price of ₹593. mfqd, uklafu, bjyml, 5merz, yn17, lnsxi, pyr7w, s20rt, zjtl, v0fx5,